Result of GM

RNS Number : 5591D

Science in Sport PLC

20 October 2022

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED BY THE COMPANY AND LIBERUM TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE EU MARKET ABUSE REGULATION WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED AND SUPPLEMENTED FROM TIME TO TIME INCLUDING BY THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019 (SI 2019/ 310).

Science in Sport plc

(" Science in Sport " or the "Company")

Result of General Meeting and Total Voting Rights

Science in Sport, the premium performance nutrition company serving elite athletes, sports enthusiasts and the gym lifestyle community, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by Shareholders. The Placing remains conditional on the admission of the 33,333,333 New Ordinary Shares to trading on AIM having become effective on or before 8.00 a.m. on 21 October 2022.

The enlarged share capital of the Company following Admission will be 172,419,741 Ordinary Shares in aggregate. Therefore the total voting rights in the Company as at 21 October 2022 will be 172,419,741. This figure may be used by Shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement shall have the meaning given to them in the Proposed Placing and Strategic Review Announcement on 30 September 2022.

For further information:

Science in Sport plc	T: 020 7400 3700
Stephen Moon, CEO Daniel Lampard, CFO
Liberum (Nominated Adviser, Broker and Sole Bookrunner)	T: 020 3100 2000
Richard Lindley Will Hall Lucas Bamber

 

END

 

 

ROMBKKBBCBDKNKB